Patents by Inventor Murielle M. Veniant-Ellison

Murielle M. Veniant-Ellison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Growth differentiation factor 15 (GDF-15) polypeptides
    Patent number: 11739131
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: August 29, 2023
    Assignee: AMGEN INC.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
    Publication number: 20220025059
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
    Type: Application
    Filed: May 27, 2021
    Publication date: January 27, 2022
    Applicant: AMGEN INC.
    Inventors: Junming YIE, Donghui SHI, David J. LLOYD, Jinghong WANG, Glenn N. SIVITS, JR., Murielle M. VENIANT-ELLISON, Renee KOMOROWSKI, Neeraj AGRAWAL, Darren L. BATES, Brandon C. P. CLAVETTE, Ian N. FOLTZ, Shu-yin HO, Christopher MURAWSKY, Xiaoshan MIN, Zhulun WANG
  • Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
    Patent number: 11046774
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Junming Yie, Donghui Shi, David J. Lloyd, Jinghong Wang, Glenn N. Sivits, Jr., Murielle M. Veniant-Ellison, Renee Komorowski, Neeraj Agrawal, Darren L. Bates, Brandon C. P. Clavette, Ian N. Foltz, Shu-yin Ho, Christopher Murawsky, Xiaoshan Min, Zhulun Wang
  • GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS
    Publication number: 20210079051
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 18, 2021
    Applicant: AMGEN INC.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. ZHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Marissa MOCK, Kenneth William WALKER
  • Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
    Patent number: 10905772
    Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: February 2, 2021
    Assignee: Amgen Inc.
    Inventors: Yuan Cheng, Chawita Netirojjanakul, Jerry Ryan Holder, Bin Wu, James R. Falsey, Bradley J. Herberich, Kelvin Sham, Leslie P. Miranda, Shu-Chen Lu, Murielle M. Veniant-Ellison, Shanaka Stanislaus, Junming Yie, Jing Xu
  • Growth differentiation factor 15 (GDF-15) constructs
    Patent number: 10894814
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: January 19, 2021
    Assignee: AMGEN INC.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Marissa Mock, Kenneth William Walker
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS
    Publication number: 20200384119
    Abstract: Method of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.
    Type: Application
    Filed: June 20, 2018
    Publication date: December 10, 2020
    Applicant: AMGEN INC.
    Inventors: Kenneth W. WALKER, Jerry Ryan HOLDER, David J. LLOYD, Shu-Chen LU, MurIelle M. VENIANT-ELLISON, Shanaka STANISLAUS
  • Growth Differentiation Factor 15 (GDF-15) Polypeptides
    Publication number: 20190315822
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 17, 2019
    Applicant: Amgen Inc.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Kenneth W. WALKER, Bryan LEMON
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
    Publication number: 20190276546
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
    Type: Application
    Filed: February 25, 2019
    Publication date: September 12, 2019
    Applicant: AMGEN INC.
    Inventors: Junming Yie, Donghui Shi, David J. Lloyd, Jinghong Wang, Glenn N. Sivits, JR., Murielle M. Veniant-Ellison, Renee Komorowski, Neeraj Agrawal, Darren L. Bates, Brandon C. P. Clavette, Ian N. Foltz, Shu-yin Ho, Christopher Murawsky, Xiaoshan Min, Zhulun Wang
  • Growth differentiation factor 15 (GDF-15) polypeptides
    Patent number: 10336798
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: July 2, 2019
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
  • Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
    Patent number: 10294303
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 21, 2019
    Assignee: AMGEN INC.
    Inventors: Junming Yie, Donghui Shi, David J. Lloyd, Jinghong Wang, Glenn N. Sivits, Jr., Murielle M. Veniant-Ellison, Renee Komorowski, Neeraj Agrawal, Darren L. Bates, Brandon C. P. Clavette, Ian N. Foltz, Shu-yin Ho, Christopher Murawsky, Xiaoshan Min, Zhulun Wang
  • GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS
    Publication number: 20180079790
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: November 29, 2017
    Publication date: March 22, 2018
    Applicant: Amgen Inc.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Marissa MOCK, Kenneth William WALKER
  • Growth Differentiation Factor 15 (GDF-15) Polypeptides
    Publication number: 20170291929
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 12, 2017
    Applicant: Amgen Inc.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Kenneth W. WALKER, Bryan LEMON
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
    Publication number: 20170275370
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
    Type: Application
    Filed: December 21, 2016
    Publication date: September 28, 2017
    Applicant: AMGEN INC.
    Inventors: Junming YIE, Donghui SHI, David J. LLOYD, Jinghong WANG, Glenn N. SIVITS, JR., Murielle M. VENIANT-ELLISON, Renee KOMOROWSKI, Neeraj AGRAWAL, Darren L. BATES, Brandon C. P. CLAVETTE, Ian N. FOLTZ, Shu-yin HO, Christopher MURAWSKY, Xiaoshan MIN, Zhulun WANG
  • Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies
    Publication number: 20170233467
    Abstract: The present disclosure provides methods of treating ocular disorders using anti-angiogenic antibodies and pharmaceutical formulations.
    Type: Application
    Filed: October 16, 2015
    Publication date: August 17, 2017
    Applicant: AMGEN INC.
    Inventors: Shu-Chen Lu, Murielle M. Veniant-Ellison, Jing Xu, Hossein Salimi-Moosavi, Jonathan Daniel Oliner